39
BioTOPics 44 | May 2012
BioTOP-Report
Epigenomics AG
Epigenomics is a molecular diagnostics com-
pany developing and commercializing a
pipeline of proprietary products for cancer.
The Company’s products enable doctors to
diagnose cancer earlier and more accurately,
leading to improved outcomes for patients.
Epigenomics’ lead product, Epi proColon
®
2.0, is a second generation blood-based test
for the early detection of colorectal cancer,
which is currently marketed in Europe and is
in development for the U.S.A.
With clinical studies indicating a majority of
colorectal cancers are detected with the test
added to the convenience of a simple blood
draw, Epi proColon
®
is expected to improve
compliance for colorectal cancer screening
and save lives through early detection of dis-
ease. Laboratory test services based on this
technology are available in the U.S.A. and
Canada by our partnering laboratories Quest,
ARUP and Warnex.
Epigenomics’ product portfolio further
includes Epi proLung
®
, a confirmatory test
aiding in the diagnosis of lung cancer that is
marketed in Europe, and additional products
in development for colorectal, lung and
prostate cancer. The Company’s technology
and products have been validated through
multiple partnerships with leading global
diagnostic companies including Abbott, QIA-
GEN, Sysmex, and Quest Diagnostics. Epig-
enomics is an international company with
operations in Berlin, Germany, and Seattle,
WA, U.S.A.
For further information please visit
www.epigenomics.com
Address
Epigenomics AG
Kleine Praesidentenstraße 1
10178 Berlin · Germany
Phone +49 30 243450
Fax
+49 30 24345555
contact@epigenomics.com
www.epigenomics.com
BioTeZ Berlin-Buch GmbH
BioTeZ is focused on biotechnological prod-
ucts and services for life science research,
pharmaceutical industry and diagnostics.
In many business fields BioTeZ has own tech-
nologies
with outstanding properties, e.g., in
the sphere of immunoaffinity columns, HRP-
labeling, sundry streptavidin coatings and
the development of enzyme immunoassays.
On the basis of many years' experience the
powerful diagnostic tool recoveryELISA
®
was
created for monitoring therapies with bio-
logics.
Business fields at a glance:
Immunoaffinity chromatography
k
Production of customized IAC
k
Coupling of different ligands,
e.g. antibodies against mycotoxins
Premium oligonucleotid synthesis
k
DNA / RNA incl. modifications
Streptavidin coating
k
Microplates
and other surfaces and
materials
k
Polystrept R for high binding capacity,
excellent for lateral flow assays
ELISA development and services
k
inclusive conjugate development,
labeling, purification etc.
Companion Diagnostics
k
recoveryELISA
®
– a new diagnostic
method to predict and to measure inter-
action between therapeutic antibodies or
biologics and their target molecules.
Contact
BioTeZ Berlin-Buch GmbH
Robert-Rössle-Straße 10
13125 Berlin · Germany
Phone +49 30 94892130
Fax
+49 30 9494509
info@biotez.de
www.biotez.de
40
BioTOPics 44 | May 2012
BioTOP-Report
Metanomics Health GmbH
Metanomics Health – a BASF Group compa-
ny – applies comprehensive Metabolite Pro-
filing (metabolomics) with biomedical data
interpretation. Metabolite Profiling is
defined as the parallel analysis of multiple
endogenous and xenobiotic metabolites in
biological systems. The core expertise of
Metanomics Health resides in discovery and
validation of biomarkers.
Technologies
k
Metabolite profiling platform with more
than 75 GC-MS and LC-MS/MS instru-
ments
k
Wide metabolite coverage via combina-
tion of unbiased and targeted platforms
k
Unique tox mode of action prediction
through MetaMap
®
Tox database
k
Excellence in systems correlation analy-
sis of complex gene function relation-
ships
Major R&D-Topics
In cooperation with academic institutes and
clinical experts Metanomics Health is run-
ning a large-scale diagnostic biomarker pro-
gram. Areas include metabolic syndrome,
heart failure, prostate cancer and multiple
sclerosis to mention a few.
Market Segments
Metanomics Health provides its services to
pharmaceutical, diagnostics and nutrition
companies. Technology applications include:
k
Mechanism of action studies
k
Mechanism of toxicity studies
k
Translational and clinical biomarker
development (e.g. PK/PD, patient stratifi-
cation, efficacy and safety markers)
k
Companion diagnostic development
k
Cell culture & bioprocess optimization
Address
Metanomics Health GmbH
Tegeler Weg 33
10589 Berlin · Germany
Contact
Dr. Tim Bölke · Managing Director
Phone +49 30 34807 400
Fax
+49 30 34807 401
company.info@metanomics-health.de
www.metanomics-health.de
Alacris Theranostics GmbH
Alacris Theranostics GmbH, operative since
September 2011, is specialised in develop-
ing new approaches in personalised medi-
cine for cancer patient diagnosis, treatment
and drug stratification. Alacris has built up a
next-generation sequencing center for the
analysis of clinical samples and applies a sys-
tems biology approach for patient and drug
stratification using the ModCell
TM
software
which is exclusively licensed to Alacris. This
approach has been originally developed in
the department of Prof. Lehrach at the Max
Planck Institute for Molecular Genetics.
Based on genome and transcriptome infor-
mation and including kinetic pathway infor-
mation, mutation and drug databases it is
providing a “Virtual Patient” model. This
”Virtual Patient” can predict the effects of
chemotherapeutic treatment and optimised
combinatory treatment for personalised
medicine approaches. ModCell
TM
also facili-
tates biomarker discovery and "Virtual Clini-
cal Trials" for patient and drug stratification.
Alacris' work provides the opportunity for:
k
finding targeted personalised treatment
for the patient
k
saving negative side effects
k
reducing health costs for non-necessary
treatment
k
optimising
stratification of drug treat-
ment
k
providing more rapid approval of drugs
in targeted non-randomised trials
k
recovering "fallen angel" drugs for the
pharmaceutical industry
k
reducing animal testing via virtual trials
Address
Alacris Theranostics GmbH
Fabeckstraße 60-62
14195 Berlin · Germany
info@alacris.de
www.alacris.de
Unlocking The Power Of
Individualised Medicine